Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-1026 in B-cell malignancies (CLL/SLL)
2020-002324-36Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suvorexant in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mature B-cell lymphoma, sponsored by Merck & Co. Primary endpoint: Dose-limiting toxicities in Part 1. Started Dec 2020; status: active.
02
Drugs
suvorexant
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2020-002324-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002324-36.